Page 53 | Certara

Case Study

Optimizing Clinical Development: Saving Time and Costs

Strategic mechanistic modeling solutions help an immunoncology biotech accelerate their clinical development of novel therapeutics.

CertaraAugust 16, 2024

Press Release

Certara Launches Phoenix™ Version 8.5 Drug Development Software

RADNOR, PA – August 15, 2024 - Certara, Inc. (Nasdaq: CERT), a global leader in…

CertaraAugust 15, 2024

Announcement

Certara Research Reveals IRA’s Impact on Biosimilar Uptake

RADNOR, PA - August 15, 2024 -- Certara, Inc., a global leader in model-informed drug…

CertaraAugust 15, 2024

Case Study

Medicines that matter: Biohaven’s Nurtec™ drug development journey

In February 2020, Biohaven Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved…

CertaraAugust 15, 2024

On-Demand Webinar

Mastering Value Storytelling in Healthcare: Leveraging Digital Tools to Meet Stakeholders’ Expectations

Everyone loves a good story. Stories are more likely to move and engage people than…

CertaraAugust 14, 2024

White Paper

Evaluating the IRA’s Impact on Medicare Part B Biosimilar Reimbursement

White paper exploring the IRA’s small but measurable impact in several key areas

CertaraAugust 13, 2024

SDTM controlled terminology - All You Need to Know

Blog

All you need to know about NCI, CDISC and SDTM controlled terminology

The use of controlled terminology (CT) is vital to successful clinical study build. In clinical…

CertaraAugust 13, 2024

Case Study

Model-Informed Confidence in Oncology Dose Selection

Discover an oncology-focused company that gained confidence in their dose selection for an AML trial…

CertaraAugust 9, 2024

Fact Sheet

Pinnacle 21 Enterprise: Dataset Validation & Submission Readiness

Explore how Pinnacle 21 Enterprise simplifies dataset validation, enhances compliance, and prepares you for regulatory…

CertaraAugust 9, 2024

Fact Sheet

Pinnacle 21 Data Exchange

CertaraAugust 9, 2024

Optimizing Clinical Development: Saving Time and Costs

Certara Launches Phoenix™ Version 8.5 Drug Development Software

Certara Research Reveals IRA’s Impact on Biosimilar Uptake

Medicines that matter: Biohaven’s Nurtec™ drug development journey

Mastering Value Storytelling in Healthcare: Leveraging Digital Tools to Meet Stakeholders’ Expectations

Evaluating the IRA’s Impact on Medicare Part B Biosimilar Reimbursement

All you need to know about NCI, CDISC and SDTM controlled terminology

Model-Informed Confidence in Oncology Dose Selection

Pinnacle 21 Enterprise: Dataset Validation & Submission Readiness

Pinnacle 21 Data Exchange

Newsletter sign up

Quick links

Solutions

Contact